No annual revenue total was found in ANAVEX LIFE SCIENCES CORP.'s SEC filings.
Anavex Life Sciences Corp. (AVXL) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances).
Revenue
—
Net income (TTM)
$-13.02M
+73.0% vs year-ago TTM
Operating cash flow (TTM)
$-29.29M
+21.0% vs year-ago TTM
Free cash flow
$-2.66M
EPS (TTM)
$-0.00
-255.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
89.35M
+5.3% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- AVXL (Nasdaq)
- Fiscal year ends
- September 30
- Headquarters
- New York, NY
- SEC filer status
- Large accelerated filer, Smaller reporting company
- SEC CIK
- 1314052
- Former names
- Thrifty Printing Inc. (until Jan 25, 2007)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Sep 30, 2025 |
FY 2024 Sep 30, 2024 |
FY 2023 Sep 30, 2023 |
FY 2022 Sep 30, 2022 |
FY 2021 Sep 30, 2021 |
|---|---|---|---|---|---|
| Operating income | -$51.4M | -$52.9M | -$55.8M | -$51.0M | — |
| Net income | -$46.4M | -$43.0M | -$47.5M | -$48.0M | -$37.9M |
| Diluted EPS | -$0.54 | -$0.52 | -$0.60 | — | — |
| Operating cash flow | -$39.0M | -$30.8M | -$27.8M | -$24.2M | -$30.4M |
| Total assets | $103.8M | $135.6M | $154.4M | $152.7M | $161.6M |
| Total liabilities | $8.9M | $15.3M | $12.5M | $10.2M | $10.8M |
| Stockholders' equity | $94.9M | $120.3M | $141.9M | $142.5M | $150.8M |
| Cash and investments | $102.6M | $132.2M | $151.0M | $149.2M | $152.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Nov 3, 2026 | Nov 1, 2026 |
| 8-K |
Current report
Officer or director change, Other events
|
Nov 2, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Other events
|
Oct 20, 2026 | Oct 20, 2026 |
| 8-K |
Current report
Other events
|
Oct 15, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Change in control, Shareholder vote results
|
Sep 28, 2026 | Sep 24, 2026 |
| 8-K |
Current report
Other events
|
Sep 9, 2026 | Sep 9, 2026 |
All 634 Anavex Life Sciences Corp. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.